The introduction of new multi-genotypic direct acting antivirals (DAA) in clinical practice has
revolutionized HCV treatment, permitting the achievement of> 95% rates of sustained …

The advent of direct-acting antivirals (DAAs) has transformed the treatment landscape of
hepatitis C. To date, over 95% of the hepatitis C virus (HCV)-infected patients who received …

Objectives To investigate the molecular characteristics of Hepatitis C Virus (HCV) detected
in patients with chronic HCV infection in Jordan. Methods The study included 48 Jordanian …

Background: Approximately 71 million people are still in need of direct-acting antiviral
agents (DAAs). To achieve the World Health Organization Hepatitis C elimination goals …

The transmission of direct-acting antiviral resistance-associated substitutions (RAS) could
hamper hepatitis C virus (HCV) cure rates and elimination efforts. A phylogenetic analysis of …

Drug resistance caused by mutations is a public health threat for existing and emerging viral
diseases. A wealth of evidence about these mutations and their clinically associated …

Direct acting antivirals (DAAs) have revolutionized hepatitis C virus (HCV) treatment, but
drug resistance could undermine proposed global elimination targets. Real‐world studies …

The advent of direct-acting antivirals (DAAs) has transformed the treatment landscape of
hepatitis C. To date, over 95% of the hepatitis C virus (HCV)-infected patients who received …

Objectives The MOSAIC study gathered data on chronic hepatitis C virus (HCV) infection
and its treatment in various countries worldwide. Here we summarise patient and HCV …

This thesis discusses the elimination of disease and burden of disease. In the first part, this
thesis outlines the cost-effectiveness of several strategies contribution to hepatitis C …